CYTOMED THERAPEUTICS LIMITED CytoMed Therapeutics Limited Share Price
Equities
GDTC
SGXZ17669631
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.255 USD | +8.94% |
|
+4.40% | -53.98% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 520K 43.37M | Sales 2025 * | 520K 43.37M | Capitalization | 26.02M 2.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -1M -83.4M | Net income 2025 * | -1M -83.4M | EV / Sales 2024 * | 41.7 x |
| Net cash position 2024 * | 4.36M 364M | Net cash position 2025 * | 2.33M 194M | EV / Sales 2025 * | 45.6 x |
| P/E ratio 2024 * |
-11.3
x | P/E ratio 2025 * |
-11.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.27% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +8.94% | ||
| 1 week | +4.40% | ||
| Current month | +6.87% | ||
| 1 month | +11.63% | ||
| 3 months | -10.16% | ||
| 6 months | -43.77% | ||
| Current year | -53.98% |
1 week
1.95
2.26
1 month
1.952.48
Current year
1.924.90
1 year
1.929.25
3 years
1.929.25
5 years
1.929.25
10 years
1.929.25
| Managers | Title | Age | Since |
|---|---|---|---|
Wee Kiat Tan
CEO | Chief Executive Officer | 36 | 01/19/01 |
Yvonne Goh
DFI | Director of Finance/CFO | 35 | 01/20/01 |
Jieming Zeng
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chee Kong Choo
FOU | Founder | 65 | 09/18/09 |
Tao Wu
BRD | Director/Board Member | 59 | 18/23/18 |
Kei Wei Leong
BRD | Director/Board Member | 49 | 18/23/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 2.255 | +8.94% | 711 |
| 14/24/14 | 2.07 | -2.36% | 242 |
| 13/24/13 | 2.12 | -0.47% | 12,182 |
| 10/24/10 | 2.13 | +0.38% | 356 |
| 09/24/09 | 2.122 | -1.76% | 5,148 |
Delayed Quote Nasdaq, May 16, 2024 at 02:00 am IST
More quotes
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company. The Company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. It is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.255
USD
Average target price
5
USD
Spread / Average Target
+121.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.98% | 23.89M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- GDTC Stock
